Farxiga CVOT1 Phase III pos. Farxiga type-1 diabetes reg. 17% sales growth; new medicines +77% incremental sales of new medicines https://markets.ft.com/data/announce/detail?dockey=1323-15830194-3PHAM0NK3GUU65HKRH6UKPAAIG Farxiga up 39% (52% CER), Product Sales increased by 13% (19% at CER) in FY 2022 to $14,631m, Growth was driven by strong Farxiga performance, … https://en.royanews.tv/news/25463/AstraZeneca-sales-rise-10-percent-in-2020 The pharmaceutical giant AstraZeneca reported a total of USD 25.8 billion in product sales and a total revenue of USD 26.6 billion for the year … https://biostock.se/en/2023/02/strong-astrazeneca-sees-continued-growth/ Farxiga developed well during the year. amounted to a total of about 4.4 BUSD in 2022, which corresponds to a growth of 46 per cent compared to … https://firstwordpharma.com/story/4627541 Farxiga: $340 million, up 36 percent ・ $338 million down 40 percent ・ with analyst estimates of $34 million https://www.reuters.com/article/world/uk/astrazeneca-sees-years-of-growth-as-drug-sales-turn-corner-idUSKCN1ND0VQ/ Product sales in the three months rose 8 percent, or 9 percent in constant currencies, which is the benchmark AstraZeneca uses for measuring the … https://finviz.com/news/306155/astrazeneca-cancer-portfolio-dominates-sales-with-massive-double-digit-growth The largest-selling drug in the segment, Farxiga, was up 7% (+2% cc) to $2.06 billion. U.S. sales jumped 6% to $6.93 billion for the quarter, https://pharmatimes.com/news/oncology_sales_drive_astrazenecas_q4_earnings_1278306/ Fasenra (benralizumab) sales reached $297 million (£231 million) in its first full year, performing exceptionally well in the countries where it … https://www.proactiveinvestors.co.uk/rns/details/1719315 Farxiga: sales milestones. 77. 57. 56. 3. (36). (38). Others. 5. n/m. n/m. 5 … 2020, added to its growing body of evidence, launching its EU Expert Advisory … https://public.tableau.com/views/Pharmarevenuesbyyear/Dashboard1?:showVizHome=no&:embed=true Unexpected Error. An unexpected error occurred. If you continue to receive this error please contact your Tableau Server Administrator. https://finchannel.com/astrazeneca-presents-new-data-on-farxiga/65617/american-business-trends/pharmacy/2017/06/ The data we are presenting at ADA underpins the safety of Farxiga and highlights the potential for earlier use of the SGLT-2 inhibitor class, …